上周，国际原油价格偏强震荡。截至2026年1月2日，纽约商品交易所西得克萨斯轻质原油期货(WTI)主 力合约结算价格为57.32美元/桶，较2025年12月26日上升1.02%；洲际交易所布伦特原油期货(Brent)主力 合约结算价格为60.75美元/桶，较2025年12月26日上升0.18%。 从现货市场看，涨幅前五名的石化产品分别为工业级碳酸锂上涨22.37%、精对苯二甲酸上涨8.32%、对 二甲苯(CFR中国)上涨6.97%、涤纶FDY上涨5.04%、页岩油上涨4.98%；跌幅前五名的石化产品分别为 液氯下跌37.72%、液化天然气下跌6.69%、纯MDI下跌4.23%、硫黄下跌3.96%、维生素D3下跌3.85%。 中化新网讯上周(2025年12月29日至31日)，仅有3个交易日，期间石油与化工指数中化工指数全部下 跌，石油指数全部上涨。 化工板块方面，化工原料指数累计下跌0.65%、化工机械指数累计下跌2.97%、化学制药指数累计下跌 2.19%、农药化肥指数累计下跌0.73%；石油板块方面，石油加工指数累计上涨6.19%、石油开采指数累 计上涨4.93%、石油贸易指数累计上涨2.66%。 从资本市 ...

12月31日刷到条新闻，美联储说未来12个月要搞超过2000亿美元的"准备金管理购买"——简单讲就是通过买短期国库券给市场"补点现金"，因为最近短期利 率涨得太快，货币市场有点"紧"。身边不少朋友问我："这事会不会影响我们手里的股票？"其实我想说，新闻只是个"引子"，真正决定股价涨跌的，从来不 是新闻本身，而是机构大资金有没有在里面"真的动起来"——去年维生素涨价那波，我算彻底看清这点了。 一、美联储的动作，不如看机构的"行动" 去年维生素D3从56元/公斤涨到265元，涨幅360%，按理说相关73只股票都该涨吧？结果23只在跌，近3成没吃到利好，有的涨翻倍有的跌腰斩。差别在哪？ 其实就一个答案：机构大资金有没有"积极交易"。 很多人以为"机构持有股票就会涨"，但其实错了——机构要是拿着股票不动，对股价一点影响都没有；只有他们真金白银地买买卖卖、积极交易的时候，才 会推动股价。就像维生素那波里的两只股票，一个机构早早就"动起来"，一个直到利好出来才短暂参与，结果完全不一样。 二、机构"动得早"，比利好更实在 有只维生素股我印象特深：2024年二季度开始，图里橙色的"机构库存"数据就一直活跃（看图2）——这数据 ...

Group 1: Industry Performance - The majority of indices in the petroleum and chemical sectors increased last week, with only the petroleum trade index declining [1] - The chemical raw materials index rose by 5.09%, the chemical machinery index by 5.46%, the chemical pharmaceuticals index by 0.14%, and the pesticide and fertilizer index by 3.86% [1] - In the petroleum sector, the petroleum processing index increased by 0.87%, and the petroleum extraction index by 1.96%, while the petroleum trade index fell by 1.60% [1] Group 2: Commodity Prices - International crude oil prices showed a strong performance, with WTI settling at $56.74 per barrel, up 0.14% from December 19, and Brent at $60.64 per barrel, up 0.28% [1] - The top five petrochemical products with price increases included battery-grade lithium carbonate up 15.29%, purified terephthalic acid up 8.32%, paraxylene (CFR China) up 7.26%, polyester FDY up 5.04%, and shale oil up 4.98% [1] - The top five petrochemical products with price declines included liquid chlorine down 37.72%, liquefied natural gas down 6.69%, pure MDI down 4.23%, sulfur down 3.96%, and vitamin D3 down 3.85% [1] Group 3: Capital Market Performance - The top five listed chemical companies with the highest stock price increases were Shenjian Co. up 61.20%, Jiuding New Materials up 48.75%, Jinlitai up 33.12%, Zaiseng Technology up 28.39%, and Dongcai Technology up 28.34% [2] - The top five listed chemical companies with the largest stock price declines were Bohai Chemical down 28.32%, Suli Co. down 13.71%, Tiantie Co. down 13.06%, Bofei Electric down 11.76%, and Kesi Co. down 10.22% [2]

证券研究报告·公司深度研究·食品加工 | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 3,103 | 3,240 | 3,696 | 4,365 | 5,047 | | 同比（%） | 3.10 | 4.43 | 14.07 | 18.11 | 15.63 | | 归母净利润（百万元） | 276.71 | 341.99 | 442.23 | 502.57 | 584.72 | | 同比（%） | 7.50 | 23.59 | 29.31 | 13.64 | 16.35 | | EPS-最新摊薄（元/股） | 0.45 | 0.56 | 0.73 | 0.82 | 0.96 | | P/E（现价&最新摊薄） | 44.15 | 35.72 | 27.63 | 24.31 | 20.89 | [Table_Tag] [Table_Summary] 投资要点 证券分析师 苏铖 执业证书：S0600524120010 such@dw ...

在引领产业高端迈进方面，中国石化先进乙烯技术突破和产业化，使我国打破国外乙烯技术的垄断，并 率先在世界上全面掌握轻质原料、重质原料及高含烯烃原料裂解技术。己内酰胺法高品质己二胺关键技 术开发与产业化拓展了乙内酰胺产品应用新途径，着力提升了产业链自主可控能力和供应链安全水平。 维生素D3系列产品绿色合成技术填补了化学法生产25-羟基维生素D3的国际空白，并拥有了完整的维生 素D3产业链。 在推动绿色低碳发展方面，多酶协同催化体系及生物基产品绿色制造技术创新与产业化实现了大宗化学 品低成本、规模化、清洁化生产工艺开发。大型多相反应过程微纳传质强化新技术在百万吨级加氢、数 十万吨级羰基化和空气氧化等生产装置上得到规模化应用，在多个产品领域打破国际巨头的垄断。 在提升装备自主化水平方面，长寿命大型乙烯裂解反应器设计制造与维护技术为国家百万吨级乙烯重大 工程建设和乙烯裂解装置安全稳定运行作出了重要贡献。面向搅拌式硫酸烷基化的绿色分离方法及成套 装备革新了传统的碱洗、水洗工艺，实现了绿色低碳变革。 中化新网讯在12月24日召开的2025全国石油和化工科技创新大会上，中国石油和化学工业联合会党委书 记、会长李云鹏总结了"十 ...

Group 1: Chemical Sector Performance - The chemical raw materials index decreased by 1.75%, while the chemical machinery index increased by 0.47%. The pharmaceutical index fell by 0.24%, and the pesticide and fertilizer index dropped by 1.48% [1] - In the petroleum sector, the petroleum processing index declined by 2.65%, the petroleum extraction index fell by 2.49%, and the petroleum trading index decreased by 7.22% [1] Group 2: Oil Price Trends - International crude oil prices decreased, with the NYMEX West Texas Intermediate crude oil futures settling at $57.44 per barrel, down 4.39% from December 5. The ICE Brent crude oil futures settled at $61.12 per barrel, down 4.13% from December 5 [1] Group 3: Petrochemical Product Price Changes - The top five petrochemical products with price increases were lithium battery electrolyte (up 5.50%), vitamin VA (up 5.21%), bisphenol A (up 4.42%), sulfuric acid (up 4.36%), and sulfur (up 4.21%) [1] - The top five petrochemical products with price decreases were liquid chlorine (down 32.88%), 2% biotin (down 5.45%), vitamin D3 (down 5.11%), aniline (down 4.36%), and DEG (down 4.15%) [1] Group 4: Capital Market Performance of Chemical Companies - The top five performing listed chemical companies were Zai Sheng Technology (up 61.19%), Guoci Materials (up 23.46%), Lanxiao Technology (up 18.13%), Qiaoyuan Co. (up 15.18%), and Yongguan New Materials (up 14.34%) [2] - The top five underperforming listed chemical companies were Fanli Technology (down 22.56%), Qingshuiyuan (down 18.42%), Hengtong Co. (down 16.12%), Letong Co. (down 15.53%), and Asia Pacific Industry (down 14.06%) [2]

Group 1: Industry Performance - The petrochemical index saw an overall increase, with six indices rising and only the chemical machinery index declining by 4.02% [1] - The chemical raw materials index rose by 3.44%, the pharmaceutical index increased by 3.09%, and the pesticide and fertilizer index went up by 3.18% [1] - In the oil sector, the oil processing index increased by 1.84%, the oil extraction index rose by 1.42%, and the oil trading index surged by 7.39% [1] Group 2: Commodity Prices - International crude oil prices experienced slight upward fluctuations, with WTI settling at $60.09 per barrel, up 0.57% from November 7, and Brent at $64.39 per barrel, up 1.19% [1] - The top five petrochemical products with the highest price increases included DMC (up 18.18%), natural rubber (up 13.22%), D4 (up 13.04%), 107 glue (up 12.71%), and methyl acrylate (up 8.03%) [1] - The five petrochemical products with the largest price declines were isooctyl acrylate (down 7.69%), 2,4-dichlorophenoxyacetic acid (down 4.29%), dichloromethane (down 3.64%), diethylene glycol (down 3.53%), and vitamin D3 (down 3.33%) [1] Group 3: Capital Market Performance - The top five listed chemical companies with the highest stock price increases were Shida Shenghua (up 43.44%), Yongtai Technology (up 33.89%), Aoke Shares (up 23.36%), Taihe Technology (up 23.59%), and Kaisheng New Materials (up 23.03%) [2] - The five listed chemical companies with the largest stock price declines included Xiangyuan New Materials (down 15.42%), Xinhang New Materials (down 14.15%), Dongcai Technology (down 13.52%), Kaili New Materials (down 12.60%), and Asia-Pacific Industry (down 11.16%) [2]

Group 1: Company Overview - Zhejiang Xinhengcheng Co., Ltd. operates two major platforms: "Chemicals+" and "Biology+" with significant growth potential in both areas [2][3] - The company focuses on a robust R&D system that integrates scientific discovery, technology, and application to enhance product effectiveness [3] Group 2: Financial Performance - In the first three quarters of 2025, the company achieved a total revenue of CNY 16.642 billion, representing a year-on-year growth of 5.45% [3] - The net profit attributable to shareholders reached CNY 5.321 billion, marking a substantial increase of 33.37% compared to the previous year [3] Group 3: Nutritional Products - The nutrition segment is the largest business area, encompassing animal and human nutrition products, including a variety of vitamins and amino acids [3][4] - Key human nutrition products include Vitamin A, D3, E, C, Coenzyme Q10, Taurine, β-Carotene, and Lycopene, with a diverse range of formulations [3] Group 4: Methionine Production - The company has a solid methionine production capacity of 300,000 tons, with an additional 70,000 tons expansion project approved and progressing well [4] - A joint venture with Sinopec for a 180,000 tons/year liquid methionine project is currently undergoing maintenance before resuming production [4] Group 5: Biochemical Fermentation - The company is optimistic about the future of its biochemical fermentation segment, focusing on products like Vitamin C and Coenzyme Q10 [5] - Plans to expand into new products in the fermentation category, including amino acids and new materials, are underway [5] Group 6: Active Pharmaceutical Ingredients - The company specializes in pharmaceutical-grade vitamins and other active pharmaceutical ingredients, providing high-quality raw materials and services to pharmaceutical companies [5] - The company has developed a water-free eye drop formulation that has achieved industry-leading status in treatment efficacy and side effect management [5] Group 7: New Materials Development - The company aims to become a key player in the new materials sector, focusing on high-performance polymers and critical intermediates [5] - The Tianjin nylon new materials project is progressing, with construction initiated in September 2025 [5][6] Group 8: Future Capital Expenditure - Future capital expenditures will be aligned with specific project developments, including the expansion of the PPS project and the establishment of a new flavoring project [6]

Core Viewpoint - Xinhecheng (002001) is committed to providing safe, healthy, and nutritious products and solutions in the human nutrition sector, with a diverse range of products including vitamins and coenzymes [1] Product Offerings - The main products include Vitamin A, Vitamin D3, Vitamin E, Vitamin C, Coenzyme Q10, Taurine, Beta-Carotene, and Lycopene, showcasing a rich product variety [1] - The company offers customized formulations based on customer needs, indicating flexibility in product development [1] Market Application - Products are widely used in various fields such as health nutrition, baking, confectionery, and beverages, highlighting the versatility of the product applications [1] - The business has a global market presence, providing raw material supply to downstream customers [1]

Financial Performance - In Q3 2025, the company achieved a revenue of 166.42 billion CNY, with a net profit attributable to shareholders of 55.41 billion CNY, reflecting a year-on-year revenue growth of 5.45% and a net profit increase of 33.37% [3] - The company has maintained steady growth through production and sales linkage, market expansion, and cost control measures [3] Product Development and Market Strategy - The company focuses on the "Chemical+" and "Biological+" strategies, targeting opportunities in nutrition products, new materials, flavoring agents, and active pharmaceutical ingredients [3] - In the human nutrition sector, the company offers a range of products including vitamins A, D3, E, C, coenzyme Q10, taurine, β-carotene, and lycopene, with a commitment to customized formulations for various applications [3] - The solid methionine production capacity is currently at 30,000 tons, with an expansion project underway [3] Strategic Partnerships and Projects - The company has partnered with Sinopec to establish a joint venture for a liquid methionine project, with a production capacity of 18,000 tons/year [3] - The nylon new materials project in Tianjin has commenced construction, focusing on an integrated production chain from adiponitrile to nylon 66 [4] Future Plans and Innovations - The company aims to enhance its core competitiveness in the new materials sector by developing high-performance polymers and key intermediates [4] - The company is expanding its flavor and fragrance segment, with plans for a new fragrance industrial park in Shandong [4] - The Heilongjiang base is focused on bio-fermentation products, with ongoing improvements in product lines and operational efficiency [4] International Expansion - Over 50% of the company's sales are from international markets, with established subsidiaries in regions including Hong Kong, Singapore, Germany, Mexico, Brazil, Japan, and Vietnam [6] - The company emphasizes overseas market expansion as part of its 2025 operational strategy [6] Employee Engagement and Incentives - The company is implementing a share buyback program with a total amount between 30 million to 360 million CNY, aimed at employee stock ownership plans to enhance motivation and align interests [6]